Azacitidine in adult patients with acute myeloid leukemia

Grants

Funding Acknowledgements

All authors equally contributed to, revised, and approved manuscript content, and approved submission to the journal. The authors received editorial support during manuscript development from Sheila Truten and Kelly Dittmore of MC2 Inc., Wynnewood, PA, who were funded by Celgene Corporation. Celgene did not contribute to content or participate in the development of this paper. The authors are fully responsible for all content and editorial decisions.